Pathways for the emergence of multi-dideoxynucleoside-resistant HIV-1 variants

AIDS

Volumn 17, Issue 8, 2003, Pages 1127-1137

  Matsumi, Shintaro ^a   Kosalaraksa, Pope ^a   Tsang, Hsinyi ^a   Kavlick, Mark F ^a   Harada, Shigeyoshi ^b   Mitsuya, Hiroaki ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti HIV agents; Multi dideoxynucleoside resistance; Reverse transcriptase; Viral fitness

Indexed keywords

2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; DIDANOSINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; ASSAY; CLONING; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ASSAY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; VIRUS REPLICATION; WILD TYPE;

ANTI-HIV AGENTS; DIDANOSINE; DIDEOXYNUCLEOSIDES; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0037867659     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200305230-00003     Document Type: Article

References (37)

1. Mitsuya H, Erickson J. Discovery and development of antiretroviral therapeutics for HIV infection. In Textbook of AIDS Medicine, 2nd edn. Edited by Merigan TC, Bartlet JG, Bolognesi D. Baltimore, MD: Williams & Wilkins; 1999:751-780.
2. Wit FW, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, et al. Outcome and predictors of failure of highly active antiretroviral therapy: one-year follow-up of a cohort of human immunodeficiency virus type 1-infected persons. J Infect Dis 1999, 179:790-798.
3. Grabar S, Pradier C, Le Corfec E, Lancar R, Allavena C, Bentata M, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS 2000, 14:141-149.
4. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999, 341:1865-1873.
5. Wainberg MA, Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998, 279:1977-1983.
6. Shirasaka T, Yarchoan R, O'Brien MC, Husson RN, Anderson BD, Kojima E, et al. Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci USA 1993, 90:562-566.
7. Shafer RW, Kozal MJ, Winters MA, Iversen AK, Katzenstein DA, Ragni MV, et al. Combination therapy with zidovudine and didanosine selects for drug- resistant human immunodeficiency virus type I strains with unique patterns of pol gene mutations. J Infect Dis 1994, 169:722-729.
8. Winters MA, Coolley KL, Girard YA, Levee DJ, Hamdan H, Shafer RW, et al. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. J Clin Invest 1998, 102:1769-1775.
9. Brenner BG, Routy JP. Petrella M, Moisi D, Oliveira M, Detorio M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002, 76:1753-1761.
10. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995, 92:2398-2402.
11. Schmit JC, Cogniaux J, Hermans P, Van Vaeck C, Sprecher S, Van Remoortel B, et al. Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. J Infect Dis 1996, 174:962-968.
12. Kavlick MF, Wyvill K, Yarchoan R, Mitsuya H. Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. J Infect Dis 1998, 177:1506-1513.
13. Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996, 70:1086-1090.
14. Huang H, Chopra R, Verdine GL, Harrison SC. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 1998, 282:1669-1675.
15. Kosalaraksa P, Kavlick MF, Maroun V, Le R, Mitsuya H. Comparative fitness of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 (HIV-1) in an in vitro competitive HIV-1 replication assay. J Virol 1999, 73:5356-5363.
16. Poch O, Sauvaget I, Delarue M, Tordo N. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989, 8:3867-3874.
17. Maeda Y, Venzon DJ, Mitsuya H. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J Infect Dis 1998, 177:1207-1213.
18. Reed LJ. Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938, 27:493-497.
19. Tanaka M, Srinivas RV, Ueno T, Kavlick MF, Hui FK, Fridland A, et al. In vitro induction of human immunodeficiency virus type I variants resistant to 2′-beta-Fluoro-2′,3′-dideoxyadenosine. Antimicrob Agents Chemother 1997, 41:1313-1318.
20. Yoshimura K, Kato R, Yusa K, Kavlick MF, Maroun V, Nguyen A, et al. JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1. Proc Natl Acad Sci USA 1999, 96:8675-8680.
21. Ueno T, Shirasaka T, Mitsuya H. Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2′,3′-dideoxynucleoside 5′-triphosphates. J Biol Chem 1995, 270;23605-23611.
22. Olivares I, Sánchez-Merino V, Martínez MA, Domingo E, López-Galíndez C, Menéndez-Arias L. Second-site reversion of a human immunodeficiency virus type 1 reverse transcriptase mutant that restores enzyme function and replication capacity. J Virol 1999, 73:6293-6298.
23. Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246:1155-1158.
24. Gu Z, Gao Q, Li X, Parniak MA, Wainberg MA. Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J Virol 1992, 66:7128-7135.
25. Kellam P, Boucher CA, Larder BA. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992, 89:1934-1938.
26. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis 1995, 171:1411-1419.
27. Boyer PL, Tantillo C, Jacobo-Molina A, Nanni RG, Ding J, Arnold E, et al. Sensitivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc Natl Acad Sci USA 1994, 91:4882-4886.
28. Sarafianos SG, Pandey VN, Kaushik N, Modak MJ. Glutamine 151 participates in the substrate dNTP binding function of HIV-1 reverse transcriptase. Biochemistry 1995, 34:7207-7216.
29. Kaushik N, Harris D, Rege N, Modak MJ, Yadav PN, Pandey VN. Role of glutamine-151 of human immunodeficiency virus type-1 reverse transcriptase in RNA-directed DNA synthesis. Biochemistry 1997, 36:14430-14438.
30. Kaushik N, Talele TT, Pandey PK, Harris D, Yadav PN, Pandey VN. Role of glutamine 151 of human immunodeficiency virus type-1 reverse transcriptase in substrate selection as assessed by site-directed mutagenesis. Biochemistry 2000, 39:2912-2920.
31. Ueno T, Mitsuya H. Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2′,3′-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry 1997, 36:1092-1099.
32. Sarafianos SG, Das K, Ding J, Boyer PL, Hughes SH, Arnold E. Touching the heart of HIV-1 drug resistance: the fingers close down on the dNTP at the polymerase active site. Chem Biol 1999, 6:R137-R146.
33. Parkina NT, Deeksb SG, Wrina MT, Yapa J, Grantc RM, Leeb KH, et al. Loss of antiretroviral drug susceptibility at low viral load during early virological failure in treatment-experienced patients. AIDS 2000, 14:2877-2887.
34. Sharma PL, Crumpacker CS. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J Virol 1997, 71:8846-8851.
35. Van Laethem K, Witvrouw M, Pannecouque C, Van Remoortel B, Schmit JC, Esnouf R, et al. Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype. AIDS 2001, 15:553-561.
36. Schmit JC, Van Laethem K, Ruiz L, Hermans P, Sprecher S, Sonnerborg A, et al. Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS 1998, 12:2007-2015.
37. Garcia-Lerma JG, Gerrish PJ, Wright AC, Qari SH, Heneine W. Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1. J Virol 2000, 74:9339-9346.